Our prognostic signature containing 10 biomarkers (TMEM236, ZNF705A, MIR663AHG, LINC00643, HOTTIP, CDKN2B-AS1, H19, hsa-miR-135a-5p, neutrophils, and Tregs) can identify GC patients with a high risk of poor prognosis. This evidence concerns the gene MIR663AHG and gastric cancer.